# Korea Clinical Trial Approvals (MFDS) - Sponsors, Phases, Sites (`cm504/korea-clinical-trials`) Actor

Newly approved drug clinical trials in South Korea from MFDS, in English: sponsor, developer, phase, indication, design, enrollment, trial sites. Search by sponsor, drug, phase or site.

- **URL**: https://apify.com/cm504/korea-clinical-trials.md
- **Developed by:** [KH C](https://apify.com/cm504) (community)
- **Categories:** Business, Lead generation
- **Features:** Limited permissions
- **Stats:** 2 total users, 1 monthly users, 100.0% runs succeeded, 0 bookmarks
- **User rating**: No ratings yet

## Pricing

from $10.00 / 1,000 clinical trials

This Actor is paid per event. You are not charged for the Apify platform usage, but only a fixed price for specific events.

Learn more: https://docs.apify.com/actors/running/actors-in-store.md#pay-per-event

## What's an Apify Actor?

An Actor is a serverless cloud program that runs on the Apify platform. It has two run modes.
In Batch mode, an Actor accepts a well-defined JSON input, performs an action which can take anything from a few seconds to a few hours,
and optionally produces a well-defined JSON output, datasets with results, or files in key-value store.
In Standby mode, an Actor provides a web server which can be used as a website, API, or an MCP server.

Apify vocabulary and the platform model are defined once, in the agent quickstart at https://apify.com/agents.md.

## How to integrate an Actor?

If asked about integration, you help developers integrate Actors into their projects.
You adapt to their stack and deliver integrations that are safe, well-documented, and production-ready.

Do not guess an integration path. Every one of them is in the agent quickstart at https://apify.com/agents.md: the Apify MCP server, Agent Skills with the Apify CLI, the JavaScript and Python clients, the REST API, and the account-free path for an agent with no human to sign in. It also carries the rule on stating cost before the first paid run.

For examples already wired to this Actor's own input schema, see the [API](#api) section below.

Each client library has reference documentation the quickstart does not restate: [JavaScript/TypeScript](https://docs.apify.com/api/client/js/docs.md) (`npm install apify-client`) and [Python](https://docs.apify.com/api/client/python/docs.md) (`pip install apify-client`).

# README

## Korea Clinical Trial Approvals (MFDS) in English

Every **drug clinical trial approved in South Korea** by the Ministry of Food and Drug Safety (MFDS, 식품의약품안전처), as clean JSON with **English titles, sponsors, developers, phases, indications and trial sites**:

- **New trial approvals, newest first**: MFDS publishes approvals within days, and this Actor returns them in one call.
- **One record per trial**, joined from two MFDS datasets: the trial plan (title, phase, status, indication, objective, design, target enrollment in total and in Korea, dates, endpoints) and the trial list (sponsor and all Korean trial sites).
- **Search** by sponsor (e.g. `IQVIA`, `Novartis`), original developer (`Pfizer`, `Hanmi`), product or code (`ABBV-400`), active ingredient, keyword, site (`Asan Medical Center`), phase, therapeutic area, status, multinational vs Korea-only, developer country and first-in-human.
- **Trial sites mode**: the 233 MFDS-designated clinical trial sites, with designation date, IRB type, region and how many trials each site has run (total since 2012 and in the last 12 months).
- **Monitoring**: schedule it daily with "only new" and receive each new approval once.

### Who uses this

- **Pharma and biotech business development**: see which companies are starting Phase 1–3 programs in Korea, with which molecule, in which indication, before results or press releases.
- **Competitive intelligence**: follow a competitor's or a molecule's trial activity in Korea (e.g. every new obesity or KRAS trial, every Chinese-originated first-in-human trial).
- **CROs and site networks**: spot new multinational trials and their sponsors and CROs, find the busiest hospitals for a phase or area, and track new site designations.
- **Licensing and investors**: screen Korean biotechs by pipeline activity (code, phase, area, enrollment).
- **AI agents and apps** that need Korean trial data through the Apify API or MCP.

### Example output

Trial (`trialIds: ["202600897"]`), long Korean text shortened:

```json
{
  "type": "clinical_trial",
  "trialId": "202600897",
  "approvalDate": "2026-11-12",
  "titleEn": "A Phase 3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects with Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Expressing c-Met Protein Level Above a Defined Cutoff",
  "titleEnSource": "MFDS",
  "titleKo": "이전에 치료를 받은 EGFR 야생형, 국소 진행성/전이성 비편평 비소세포폐암이 ...",
  "phase": "Phase 3",
  "status": "Approved, not yet recruiting",
  "sponsorEn": "AbbVie Korea Ltd.",
  "sponsorKo": "한국애브비(주)",
  "developerEn": "AbbVie Inc.",
  "productName": "ABBV-400",
  "therapeuticArea": "Oncology",
  "therapeuticSubArea": "Targeted therapy",
  "conditionEn": "Non-squamous Non-small Cell Lung Cancer",
  "conditionKo": "비편평 비소세포폐암",
  "objectiveEn": "Primary objectives are as follows:\n• To evaluate the efficacy of telisotuzumab adizutecan compared with standard therapy, measured by OR per OS and/or BICR assessment. ...",
  "purpose": "Marketing authorization",
  "developmentOrigin": "Developed outside Korea",
  "scope": "Multinational",
  "design": { "type": "Parallel", "randomized": true, "blinding": "Open", "arms": 2 },
  "firstInHuman": false,
  "activeComparator": true,
  "placeboControlled": false,
  "comparatorKo": "라무시루맙,도세탁셀",
  "dosageFormsEn": ["Lyophilized powder for solution for injection"],
  "targetEnrollment": 660,
  "targetEnrollmentKorea": 30,
  "plannedPeriod": { "from": "2027-02", "to": "2031-04" },
  "primaryEndpointsKo": "• RECIST 버전 1.1에 따른 BICR 평가에 기반한 OR\n• OS",
  "sites": [
    { "nameEn": "Korea University Guro Hospital", "nameKo": "고려대학교 의과대학 부속 구로병원" },
    { "nameEn": "Samsung Medical Center", "nameKo": "삼성서울병원" },
    { "nameEn": "National Cancer Center Korea", "nameKo": "국립암센터" },
    { "nameEn": "Severance Hospital, Yonsei University College of Medicine", "nameKo": "연세대학교의과대학세브란스병원" }
  ],
  "siteCount": 7,
  "sponsorRegion": "Seoul",
  "detailLevel": "full",
  "source": "https://www.data.go.kr/data/15090589/openapi.do"
}
```

Trial site (`mode: sites`, `site: Samsung`):

```json
{
  "type": "trial_site",
  "siteId": "19",
  "nameEn": "Samsung Medical Center",
  "nameKo": "삼성서울병원",
  "designationDate": "1997-03-11",
  "irbType": "Own IRB",
  "addressKo": "서울특별시 강남구",
  "region": "Seoul",
  "trialCount": 3723,
  "trialsLast12Months": 303,
  "latestTrialApprovalDate": "2026-11-12"
}
```

Each trial also carries dosing period, first/last subject enrolled and last-visit dates (when reported), secondary endpoints, administration method, dosage form in Korean, the original developer's country, and the latest amendment approval date.

### Input examples

Newest approvals (default):

```json
{ "mode": "trials", "maxItems": 10 }
```

All Phase 1 trials at a hospital this year:

```json
{ "site": "Asan Medical Center", "phases": ["phase1"], "since": "2026-01-01", "maxItems": 100 }
```

A company's trials (sponsor = the applicant in Korea, often the local subsidiary or the CRO):

```json
{ "sponsor": "IQVIA", "since": "2026-01-01", "maxItems": 200 }
```

Competitive watch, daily schedule:

```json
{ "keyword": "obesity", "onlyNew": true, "monitorName": "obesity-watch", "maxItems": 50 }
```

Chinese-originated first-in-human oncology trials, multinational:

```json
{ "therapeuticAreas": ["Oncology"], "developerCountry": "China", "firstInHumanOnly": true, "scope": "multinational", "maxItems": 20 }
```

Trial sites with trial counts:

```json
{ "mode": "sites", "region": "Seoul", "maxItems": 100 }
```

### Pricing

Pay per result, nothing else:

| Result | Event | Price |
|---|---|---|
| Clinical trial | `clinical-trial` | $0.01 |
| Trial site | `trial-site` | $0.003 |

English titles, names and translations are included.

### Data and English

- Source: Ministry of Food and Drug Safety (MFDS) via data.go.kr (datasets 15090589 clinical trial plan details, 15056835 clinical trial information, 15058129 clinical trial sites), license: no usage restrictions (이용허락범위 제한 없음). This Actor is not affiliated with the MFDS.
- `titleEn` is the official English title filed with MFDS when there is one (`titleEnSource: "MFDS"`, about 70% of trials); otherwise it is translated by AI (`"AI"`).
- Phases, statuses, areas, design, dosage forms and countries are mapped to English with fixed tables. Sponsor, developer and site names come from a reviewed English name table covering every name seen so far; new names, conditions, objectives and Korean product/ingredient names are translated by AI (Claude) when "Translate missing English" is on. Korean originals are always included.

### FAQ

**How current is it?** MFDS updates the datasets in near real time; new approvals usually appear within a few days of approval.

**What is covered?** Full trial details for approvals since January 2019 (about 8,300 trials, roughly 900–1,300 per year). Approvals from 2012 to 2018 (about 6,000) come from the trial list with basic fields only (`detailLevel: "basic"`: title, sponsor, phase, product, sites). Medical device trials are not included.

**Sponsor vs developer?** `sponsor` is the applicant that filed the trial in Korea (a local subsidiary, a Korean company, a hospital for investigator-initiated trials, or a CRO acting for a foreign sponsor). `developer` is the company that owns the investigational product.

**Searching English drug names?** Sponsors register ingredients in English or Korean. `ingredient: "semaglutide"` finds the English entries; add the Korean name (`세마글루티드`) for the rest, or use `keyword`, which also matches English titles.

**Why does a site show 0 trials?** Trial counts match the site's name in the trial list exactly; a few sites are listed under a different name there.

**Limits?** `maxItems` caps the results. Searches without a product, ingredient or developer scan approvals newest first and stop when enough results are found.

# Actor input Schema

## `mode` (type: `string`):

Choose the task.

## `keyword` (type: `string`):

Trials only. English or Korean, case-insensitive, e.g. obesity, NSCLC, KRAS, 비만. Matched against the English title (where MFDS has one), the Korean title, condition, product and ingredient.

## `sponsor` (type: `string`):

Trials only. The company or institution that filed the trial in Korea (often the local subsidiary or a CRO), English or Korean, e.g. Novartis, IQVIA, 한미약품. Covers approvals since 2012.

## `developer` (type: `string`):

Trials only. The company that owns the drug, e.g. Pfizer, AstraZeneca, Hanmi, 유한양행.

## `product` (type: `string`):

Trials only. Investigational product name or development code, e.g. ABBV-400, HCP1701, DW5524.

## `ingredient` (type: `string`):

Trials only. As registered (English or Korean, sponsors use both), e.g. semaglutide, 세마글루티드, tirzepatide.

## `site` (type: `string`):

Trials: only trials run at this site. Sites: filter the site list. English or Korean, e.g. Asan Medical Center, Samsung Medical Center, 서울대학교병원.

## `phases` (type: `array`):

Trials only. Combined phases (e.g. 1/2) match both.

## `therapeuticAreas` (type: `array`):

Trials only (approvals since 2019).

## `statuses` (type: `array`):

Trials only (approvals since 2019).

## `scope` (type: `string`):

Trials only.

## `purpose` (type: `string`):

Trials only.

## `developerCountry` (type: `string`):

Trials only, e.g. United States, Japan, China, South Korea.

## `firstInHumanOnly` (type: `boolean`):

Trials only.

## `trialIds` (type: `array`):

Trials only: fetch these MFDS trial serial numbers (e.g. 202600897) and ignore the other filters.

## `region` (type: `string`):

Sites only, e.g. Seoul, Busan, Gyeonggi-do.

## `includeSiteStats` (type: `boolean`):

Sites only: total approved trials since 2012, trials in the last 12 months and the latest approval date at each site.

## `since` (type: `string`):

YYYY-MM-DD. Full trial details exist from 2019; earlier approvals (from 2012) come with basic fields. Sites: designated on or after.

## `until` (type: `string`):

YYYY-MM-DD.

## `onlyNew` (type: `boolean`):

For scheduled monitoring: skip trials (or sites) already returned by a previous run with the same monitor name.

## `monitorName` (type: `string`):

Keeps separate 'only new' memories for different schedules.

## `translateToEnglish` (type: `boolean`):

Titles without an official English version, conditions, objectives and names not in our tables are translated by Claude (Anthropic). Korean originals are always included.

## `maxItems` (type: `integer`):

Stop after this many results.

## Actor input object example

```json
{
  "mode": "trials",
  "keyword": "",
  "sponsor": "",
  "developer": "",
  "product": "",
  "ingredient": "",
  "site": "",
  "phases": [],
  "therapeuticAreas": [],
  "statuses": [],
  "scope": "all",
  "purpose": "all",
  "developerCountry": "",
  "firstInHumanOnly": false,
  "trialIds": [],
  "region": "",
  "includeSiteStats": true,
  "onlyNew": false,
  "monitorName": "default",
  "translateToEnglish": true,
  "maxItems": 10
}
```

# Actor output Schema

## `results` (type: `string`):

Clinical trial or trial site records, depending on the task.

# API

You can run this Actor programmatically using our API. Below are code examples in JavaScript, Python, and CLI, as well as the OpenAPI specification and MCP server setup.

## JavaScript example

```javascript
import { ApifyClient } from 'apify-client';

// Initialize the ApifyClient with your Apify API token
// Replace the '<YOUR_API_TOKEN>' with your token
const client = new ApifyClient({
    token: '<YOUR_API_TOKEN>',
});

// Prepare Actor input
const input = {
    "maxItems": 10
};

// Run the Actor and wait for it to finish
const run = await client.actor("cm504/korea-clinical-trials").call(input);

// Fetch and print Actor results from the run's dataset (if any)
console.log('Results from dataset');
console.log(`💾 Check your data here: https://console.apify.com/storage/datasets/${run.defaultDatasetId}`);
const { items } = await client.dataset(run.defaultDatasetId).listItems();
items.forEach((item) => {
    console.dir(item);
});

// 📚 Want to learn more 📖? Go to → https://docs.apify.com/api/client/js/docs

```

## Python example

```python
from apify_client import ApifyClient

# Initialize the ApifyClient with your Apify API token
# Replace '<YOUR_API_TOKEN>' with your token.
client = ApifyClient("<YOUR_API_TOKEN>")

# Prepare the Actor input
run_input = { "maxItems": 10 }

# Run the Actor and wait for it to finish
run = client.actor("cm504/korea-clinical-trials").call(run_input=run_input)

# Fetch and print Actor results from the run's dataset (if there are any)
print(f"💾 Check your data here: https://console.apify.com/storage/datasets/{run.default_dataset_id}")
for item in client.dataset(run.default_dataset_id).iterate_items():
    print(item)

# 📚 Want to learn more 📖? Go to → https://docs.apify.com/api/client/python/docs/quick-start

```

## CLI example

```bash
echo '{
  "maxItems": 10
}' |
apify call cm504/korea-clinical-trials --silent --output-dataset

```

## MCP server setup

```json
{
    "mcpServers": {
        "apify": {
            "type": "http",
            "url": "https://mcp.apify.com/?tools=fetch-actor-details,cm504/korea-clinical-trials"
        }
    }
}
```

The hosted server signs you in with OAuth on first connect, so no API token belongs in this config. Clients without OAuth support can send an `Authorization: Bearer <APIFY_API_TOKEN>` header instead, using a token from API & Integrations in Apify Console (https://console.apify.com/settings/integrations).

## OpenAPI specification

Download the OpenAPI definition: https://api.apify.com/v2/actors/c0Tg2h2XtmhvofQZF/builds/rMt1upwj4C6yWRg0w/openapi.json
